



# MARKET RELEASE

28 March 2017

## **Zelda Therapeutics Limited**

### **TRADING HALT**

The securities of Zelda Therapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 30 March 2017, or when the announcement is released to the market.

Security Code:                   ZLD

Ben Secrett  
**Senior Adviser, Listings Compliance (Perth)**



28 March 2017

Australian Securities Exchange Limited  
40 Central Park  
152 – 158 St Georges Terrace  
PERTH WA 6000

Attention: Chris Bailey  
By email only: chris.bailey@asx.com.au

Dear Sir

#### TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelda Therapeutics Limited (ASX: ZLD) requests the granting of a trading halt in ZLD's ordinary securities listed on the ASX pending the release of an announcement concerning a capital raising.

It is requested that the trading halt apply immediately until the earlier of ZLD making the announcement concerning a capital raising, or the opening of trading on Thursday, 30 March 2017.

ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

Tim Slate  
Company Secretary

Corporate  
Mr Harry Karelis  
Executive Chairman  
Mobile: +61 413 056 328  
hkarelis@zeldatherapeutics.com

Investors  
Dr Stewart Washer  
Executive Director  
Mobile: +61 418 288 212  
swasher@zeldatherapeutics.com



About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.